CN109311832A - 沃替西汀的帕莫酸盐及其晶型 - Google Patents

沃替西汀的帕莫酸盐及其晶型 Download PDF

Info

Publication number
CN109311832A
CN109311832A CN201780016707.3A CN201780016707A CN109311832A CN 109311832 A CN109311832 A CN 109311832A CN 201780016707 A CN201780016707 A CN 201780016707A CN 109311832 A CN109311832 A CN 109311832A
Authority
CN
China
Prior art keywords
crystal form
vortioxetine
powder diffraction
ray powder
hydrochlorate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780016707.3A
Other languages
English (en)
Other versions
CN109311832B (zh
Inventor
李云飞
夏小二
许昕
张瑱
刘磊
张小娟
张立明
李东升
王艺瑾
葛建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Original Assignee
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Synergy Pharmaceutical Sciences Co Ltd filed Critical Shanghai Synergy Pharmaceutical Sciences Co Ltd
Publication of CN109311832A publication Critical patent/CN109311832A/zh
Application granted granted Critical
Publication of CN109311832B publication Critical patent/CN109311832B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本发明提供了一种沃替西汀的帕莫酸盐，其包括沃替西汀帕莫酸盐的晶型物、溶剂化物或无定形物。本发明提供了所述沃替西汀的帕莫酸盐及其晶型的制备方法和应用。本发明所制备的沃替西汀帕莫酸盐延长了沃替西汀在体内的滞留时间，实现了沃替西汀在体内的缓慢释放，适用于长效药物剂型的制备。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201780016707.3A 2016-03-29 2017-03-28 沃替西汀的帕莫酸盐及其晶型 Active CN109311832B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016101876394 2016-03-29
CN201610187639 2016-03-29
PCT/CN2017/078427 WO2017167180A1 (zh) 2016-03-29 2017-03-28 沃替西汀的帕莫酸盐及其晶型

Publications (2)

Publication Number Publication Date
CN109311832A true CN109311832A (zh) 2019-02-05
CN109311832B CN109311832B (zh) 2023-01-06

Family

ID=59962591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780016707.3A Active CN109311832B (zh) 2016-03-29 2017-03-28 沃替西汀的帕莫酸盐及其晶型

Country Status (7)

Country Link
US (1) US10793536B2 (zh)
EP (1) EP3438099A1 (zh)
JP (1) JP6669932B2 (zh)
CN (1) CN109311832B (zh)
AU (1) AU2017242867B9 (zh)
CA (1) CA3018402C (zh)
WO (1) WO2017167180A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111925294A (zh) * 2020-07-06 2020-11-13 济南大学 一种托特罗定帕莫酸盐及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215636A1 (zh) * 2016-06-16 2017-12-21 广东东阳光药业有限公司 二芳基硫醚哌嗪类化合物及其制备方法和用途
WO2018086534A1 (zh) * 2016-11-09 2018-05-17 广东东阳光药业有限公司 氢溴酸沃替西汀长效注射制剂
CN108250064A (zh) * 2018-04-20 2018-07-06 梧州学院 沃替西汀-二羟基苯甲酸新盐型及其制备方法
CN110934868A (zh) * 2018-09-21 2020-03-31 合肥合源药业有限公司 难溶性复合物、药物组合物及其应用
CN109134352A (zh) * 2018-09-21 2019-01-04 合肥锐思生物医药有限公司 一种制备难溶性复合物或其溶剂合物的方法
US20220119338A1 (en) * 2019-01-11 2022-04-21 Alar Pharmaceuticals Inc. Ketamine pamoate and use thereof
CN114965720B (zh) * 2021-02-20 2024-02-23 成都康弘药业集团股份有限公司 一种测定氢溴酸伏硫西汀有关物质的方法
WO2022199707A1 (zh) * 2021-03-26 2022-09-29 上海博志研新药物技术有限公司 哌马色林药用盐、制备方法、含其的药物组合物及应用
CN117597111A (zh) 2021-08-05 2024-02-23 浙江华海药业股份有限公司 一种沃替西汀帕莫酸盐冻干粉针剂及其制备方法
CN115702894A (zh) * 2021-08-11 2023-02-17 朱信红 一种用于止吐的缓释组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614179A (zh) * 2006-06-16 2012-08-01 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
US20140243278A1 (en) * 2011-07-05 2014-08-28 Sunil Sadanand Nadkarni Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
CN104039765A (zh) * 2011-11-29 2014-09-10 顾自强 多奈哌齐双羟萘酸盐、制备方法及其应用
CN109311833A (zh) * 2016-06-16 2019-02-05 广东东阳光药业有限公司 二芳基硫醚哌嗪类化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
US9822086B2 (en) * 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614179A (zh) * 2006-06-16 2012-08-01 H.隆德贝克有限公司 作为用于治疗认知损伤的、具有结合的对血清素再吸收、5-ht3和5-ht1a活性的化合物的1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪
US20140243278A1 (en) * 2011-07-05 2014-08-28 Sunil Sadanand Nadkarni Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
CN104039765A (zh) * 2011-11-29 2014-09-10 顾自强 多奈哌齐双羟萘酸盐、制备方法及其应用
CN109311833A (zh) * 2016-06-16 2019-02-05 广东东阳光药业有限公司 二芳基硫醚哌嗪类化合物及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111925294A (zh) * 2020-07-06 2020-11-13 济南大学 一种托特罗定帕莫酸盐及其制备方法

Also Published As

Publication number Publication date
CN109311832B (zh) 2023-01-06
AU2017242867A1 (en) 2018-10-11
CA3018402C (en) 2021-05-11
AU2017242867A8 (en) 2018-10-25
WO2017167180A1 (zh) 2017-10-05
US10793536B2 (en) 2020-10-06
EP3438099A4 (en) 2019-02-06
JP2019515024A (ja) 2019-06-06
AU2017242867B9 (en) 2019-07-04
EP3438099A1 (en) 2019-02-06
JP6669932B2 (ja) 2020-03-18
US20190169147A1 (en) 2019-06-06
CA3018402A1 (en) 2017-10-05
AU2017242867B2 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
CN109311832A (zh) 沃替西汀的帕莫酸盐及其晶型
AU2006301708B2 (en) Glycyrrhetinic acid-30-amide derivatives and the uses thereof
WO2020030143A1 (zh) 酮酰胺类化合物及其制备方法、药物组合物和用途
AU2011213431B2 (en) Polymorphs of dasatinib, preparation methods and pharmaceutical compositions thereof
JP7050336B2 (ja) 重水素化化合物及びその医薬的用途
JP2021523880A (ja) ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用
CN104364240A (zh) 一种用于预防或治疗分支杆菌疾病的药物
WO2023198197A1 (zh) 一种游离态plx5622晶型及其制备方法
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
US10947185B2 (en) Crystal form of dezocine and preparation method therefor
TWI668222B (zh) 5型磷酸二酯酶抑制劑的甲磺酸鹽多晶物及其製備方法和應用
WO2022258060A1 (zh) 一种lanifibranor的晶型及其制备方法
BRPI0806461A2 (pt) composto, e, composição farmacêutica para a prevenção ou tratamento das infecções virais
EP4204405A1 (en) Polymorphs of an ssao inhibitor
WO2020224208A1 (zh) 吡啶酮衍生物的晶型及制备方法和应用
ES2778434T3 (es) Composiciones supersaturadas de compuestos de benzimidazol
WO2023221981A1 (en) Taxamairin analogs and methods of use thereof
WO2024056079A1 (zh) 内匹司他酸加成盐的多晶型及其制备方法和用途
WO2023185931A1 (zh) 一种p2x3抑制剂化合物及其盐、多晶型和用途
WO2012007952A1 (en) Novel polymorph of irinotecan hydrochloride
JP5589097B2 (ja) ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
WO2017152846A1 (zh) 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
CN112876510A (zh) 一种磷酸酯类多环化合物及其药物组合物和用途
WO2019166962A1 (en) Deutetrabenazine polymorphs and methods for their preparation
TW201904972A (zh) 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Li Yunfei

Inventor after: Ge Jian

Inventor after: Xia Xiaoer

Inventor after: Xu Xin

Inventor after: Zhang Tian

Inventor after: Liu Lei

Inventor after: Zhang Xiaojuan

Inventor after: Zhang Liming

Inventor after: Li Dongsheng

Inventor after: Wang Yijin

Inventor before: Li Yunfei

Inventor before: Ge Jian

Inventor before: Xia Xiaoer

Inventor before: Xu Xin

Inventor before: Zhang Tian

Inventor before: Liu Lei

Inventor before: Zhang Xiaojuan

Inventor before: Zhang Liming

Inventor before: Li Dongsheng

Inventor before: Wang Yijin

GR01 Patent grant
GR01 Patent grant